We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Celyad Oncology SA | NASDAQ:CYAD | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.47 | 0.47 | 0.52 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of April 2019
Commission File Number: 001-37452
CELYAD SA
(Translation of registrants name into English)
Rue Edouard Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Celyad SA
On March 28, 2019, Celyad SA (the Company ) issued a press release announcing the appointment of Mr. Filippo Petti as Chief Executive Officer ( CEO ), effective April 1, 2019. Mr. Petti, who previously served as the Companys Chief Financial Officer ( CFO ), will continue to serve as interim CFO until a permanent CFO is appointed by the Board. Dr. Christian Homsy, the Companys previous CEO, will continue to serve as a non-executive director and the chair of the Strategy Committee of the Board of Directors. A copy of the Companys press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On March 28, 2019, the Company also issued a press release announcing its 2018 financial and operating results. A copy of the Companys press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
The information contained in this Current Report on Form 6-K, including Exhibits 99.1 and 99.2, except for the quotes of Michael Lussier, Filippo Petti and Christian Homsy contained in Exhibit 99.1 and the quotes of Christian Homsy contained in Exhibit 99.2, is hereby incorporated by reference into the Companys Registration Statements on Forms F-3 (File No. 333-220285) and S-8 (File No. 333-220737).
EXHIBITS
Exhibit |
Description |
|
99.1 | Press release issued by the registrant on March 28, 2019 | |
99.2 | Press release issued by the registrant on March 28, 2019 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CELYAD SA | ||||||
Date: April 3, 2019 | By: |
/s/ Filippo Petti |
||||
Filippo Petti Chief Executive Officer and Financial Officer |
1 Year Celyad Oncology Chart |
1 Month Celyad Oncology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions